High-flux hemodialysis versus glucarpidase for methotrexate-associated acute kidney injury: What’s best?
Journal of Onco-Nephrology · 2019
DOI: 10.1177/2399369319827305 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Onco-Nephrology, 2019. Verfasst von Abhijat Kitchlu und 1 weiteren Autor:innen. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Kidney-related adverse drug effects from chemotherapeutic agents can cause acute kidney injury that may influence cancer treatment and patient outcomes. Many current chemotherapy drugs are associated with acute kidney injury, including methotrexate which causes dose-dependent tubular injury. In this review, we will focus on the manifestations of kidney disease secondary to methotrexate and discuss management strategies. In particular, we will review the use of high-flux hemodialysis versus glucarpidase for reducing toxic serum levels of methotrexate.
Zitieren
APA
Kitchlu, A., & Shirali, A. C. (2019). High-flux hemodialysis versus glucarpidase for methotrexate-associated acute kidney injury: What’s best?. Journal of Onco-Nephrology. https://doi.org/10.1177/2399369319827305
Vancouver
Kitchlu A, Shirali AC. High-flux hemodialysis versus glucarpidase for methotrexate-associated acute kidney injury: What’s best?. Journal of Onco-Nephrology. 2019. doi:10.1177/2399369319827305
BibTeX
@article{Kitchlu2019,
author = {Kitchlu, Abhijat and Shirali, Anushree C},
title = {High-flux hemodialysis versus glucarpidase for methotrexate-associated acute kidney injury: What’s best?},
journal = {Journal of Onco-Nephrology},
year = {2019},
doi = {10.1177/2399369319827305}
}
EUVIMED